Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DMBT1
REST API REST API
Homo sapiens
DMBT1 is differentially expressed in 156 experiments: 94 organism parts: lung, trachea, ... (92 more);, 86 disease states: normal, acute promyelocytic leukemia, ... (84 more);, 37 cell types 163 cell lines 8 compound treatments and 59 other conditions.
Synonyms GP340, muclin
Orthologs DMBT1 (Bos taurus)   Dmbt1 (Rattus norvegicus)   DMBT1 (Gallus gallus)   Dmbt1 (Mus musculus)   ENSCAFG00000025572 (Canis familiaris)   ENSCAFG00000012561 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term extrinsic to membrane, protein binding, response to wounding, cytoplasm, intracellular, scavenger receptor activity, innate immune response, membrane, proteinaceous extracellular matrix, extracellular region, induction of bacterial agglutination, cell differentiation, tissue regeneration, multicellular organismal development, calcium-dependent protein binding, pattern recognition receptor activity, extracellular matrix, protein transport, inner cell mass cell proliferation, phagocytic vesicle membrane, zymogen granule membrane, response to estrogen stimulus, response to virus, blastocyst development, interspecies interaction between organisms, positive regulation of epithelial cell differentiation, response to organic substance, Gram-positive bacterial cell surface binding, epithelial cell differentiation, Gram-negative bacterial cell surface binding, zymogen binding, pattern recognition receptor signaling pathway
InterPro Term CUB, Srcr_rcpt, Srcr_rcpt-rel, Zona_pellucida_Endoglin/CD105
UniProt Accession Q9UGM3, B6V682, A6NDZ5, F8WEF7
Gene-Disease Assocation GLIOMA SUSCEPTIBILITY 1; GLM1, MEDULLOBLASTOMA; MDB
Search EB-eye ENSG00000187908
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-11078, E-GEOD-17189, E-GEOD-803, E-AFMX-5, E-GEOD-22541, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-22639, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, E-GEOD-24147, ... (19 experiments)

Factor Value U/D Experiments
MDAMB453
2
E-MTAB-37, E-MTAB-62
NCIH1395
1
E-MTAB-37
NCIH810
1
E-MTAB-37
UMUC3
1
E-MTAB-37
SEM
1
E-MTAB-37
TERV-ST110
1
E-MTAB-62
157 more value(s).


Cell type

studied in E-GEOD-15893, E-GEOD-10797, E-AFMX-5, E-GEOD-18811, E-MEXP-1121, ... (23 experiments)

Factor Value U/D Experiments
stromal cell
1
3
E-MEXP-2034, E-GEOD-1460, E-MEXP-1121, E-GEOD-10797
memory B cell
1
E-TABM-702
epidermoid
1
E-GEOD-19397
neutrophil
1
E-GEOD-12662
endothelial cell
1
E-GEOD-3998
spermatid
1
E-TABM-130
31 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2069, E-GEOD-2549, E-GEOD-20602, ... (33 experiments)

Factor Value U/D Experiments
Crohn's disease
4
1
E-GEOD-3365
monoclonal gammopathy of uncertain significance
1
E-MTAB-372
Breast adenocarcinoma
1
E-MTAB-62
Burkitt's lymphoma
2
1
E-MTAB-37
Down syndrome
1
E-GEOD-5390
carcinoma in situ lesion
1
E-GEOD-3167
80 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-412, E-GEOD-5824, E-GEOD-7307, E-GEOD-20081, ... (6 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-5824, E-GEOD-412
Cxcl12
1
E-GEOD-7307
bacterial endotoxin
1
1
E-GEOD-3284
not specified
1
E-GEOD-20081
hydroxyurea
1
1
E-GEOD-6431
dimethyl sulfoxide
6
1
E-GEOD-5824
2 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
34
1
1
E-GEOD-21653


Biosource provider
studied in E-TABM-325, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-21138

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-20847

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-1153

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-1446, E-GEOD-22278, E-GEOD-837 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-176, E-GEOD-1926, E-GEOD-6919, E-GEOD-16363, E-MEXP-1883, ... (19 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-21750

Pn
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

RNAi
studied in E-GEOD-1703, E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-22541

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.608 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM